Logicbio Therapeutics (LOGC) Gets a Buy Rating from Chardan Capital
Chardan Capital analyst Geulah Livshits maintained a Buy rating on Logicbio Therapeutics (LOGC) yesterday and set a price target of $20.00. The company’s shares closed last Monday at $10.45.
According to TipRanks.com, Livshits is a 4-star analyst with an average return of 11.5% and a 64.7% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Rocket Pharmaceuticals, and Crispr Therapeutics AG.
Logicbio Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $20.00.
See today’s analyst top recommended stocks >>
Based on Logicbio Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $10.92 million. In comparison, last year the company had a GAAP net loss of $7.06 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
LogicBio Therapeutics, Inc. is a genome editing company, which engages in developing medicines to treat rare diseases in patients with significant unmet medical need. It focuses on the commercialization of specific genome editing and integration of the therapeutic transgene.